chronic myeloproliferative disorder: A clonal hematopoietic stem cell disorder, characterized by proliferation in the bone marrow of one or more of the myeloid (i.e., granulocytic, erythroid, megakaryocytic, and mast cell) lineages. It is primarily a neoplasm of adults. (WHO 2008)
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
473681 |
1. Apply sex-specific ruleNone |
473681 |
2. Check conditionsNone |
473681 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
396 |
4. Check minimum number of eventsNone |
396 |
5. Include endpointsNone |
396 |
6. Filter based on genotype QC (FinnGen only) |
382 |
Control definitions (FinnGen only)
Control exclude
MYELOPROF
Extra metadata
First used in FinnGen datafreeze
DF2, additional
Chronic myeloproliferative disease
based on the number of shared cases.
Similar with more cases:
Similar with less cases:
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 2801 | 1352 | 1414 |
| Only index persons | 2074 | 1031 | 1043 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.04 | 0.04 | 0.04 |
| Only index persons | 0.04 | 0.04 | 0.04 |
| Median age at first event (years) | |||
| Whole population | 70.78 | 71.37 | 70.24 |
| Only index persons | 69.56 | 69.80 | 69.34 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 382 | 173 | 209 |
| Unadjusted period prevalence (%) | 0.09 | 0.07 | 0.10 |
| Median age at first event (years) | 67.06 | 65.82 | 68.09 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
Mortality – FinRegistry
↥Association
Association between endpoint CHRONMYELOPRO and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| CHRONMYELOPRO | 4.416 [3.64, 5.36] | < 0.001 |
| Birth year | 0.996 [0.99, 1.0] | 0.395 |
During the follow-up period (1.1.1998 — 31.12.2019), 638 out of 1093 females with CHRONMYELOPRO died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| CHRONMYELOPRO | 4.304 [3.38, 5.49] | < 0.001 |
| Birth year | 0.988 [0.98, 1.0] | 0.008 |
During the follow-up period (1.1.1998 — 31.12.2019), 708 out of 1119 males with CHRONMYELOPRO died.
Mortality risk
Mortality risk for people of age
years, who have CHRONMYELOPRO.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.402% | 0.735% |
| 5 | 2.414% | 4.819% |
| 10 | 6.333% | 12.442% |
| 15 | 12.699% | 21.902% |
| 20 | 20.929% | 35.833% |
Relationships between endpoints
↥Index endpoint: CHRONMYELOPRO – Chronic myeloproliferative disease
GWS hits: 2
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
Extremity
rg [CI]
Extremity
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data